Assessing asthma patients' views on the environmental impact of inhalers
Patient and Prescriber Perspective on Climate Impact of Inhalers in the Treatment of Asthma
This study looks at how asthma patients feel about switching their inhalers to help the environment and whether doctors are willing to support those changes.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | McGill University Health Centre/Research Institute of the McGill University Health Centre Academic / other |
| Locations | 1 site (Montréal, Quebec) |
| Trial ID | NCT06097507 on ClinicalTrials.gov |
What this trial studies
This study evaluates asthma patients' willingness to switch inhalers for environmental reasons and the readiness of prescribers to accommodate such requests. It focuses on the significant carbon footprint differences between metered dose inhalers (MDI) and dry powder inhalers (DPI). The study will also measure patient awareness regarding the climate impact of inhalers and the importance they place on this issue compared to other factors like cost and ease of use. Educational interventions will be provided to enhance understanding of these impacts.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with a confirmed diagnosis of asthma who are stable and using inhaled steroids along with a Ventolin MDI.
Not a fit: Patients who are currently experiencing an acute asthma exacerbation or have had recent emergency room visits for asthma may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more environmentally friendly inhaler choices for asthma patients, reducing the carbon footprint of asthma management.
How similar studies have performed: Previous studies in the UK have shown that patient awareness of inhaler climate impact is low, but willingness to change after education is high, indicating potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 18 years of age or older * Followed in the asthma clinic at the Montreal Chest Institute or the Montreal General Hospital. * Confirmed diagnosis of asthma presenting for a follow up visit for their asthma (defined as positive methacholine challenge test or confirmed reversibility of lung function 12% increase FEV1 (forced expiratory volume) or 200ml absolute value increase post bronchodilator). * On an inhaled steroid for the treatment of asthma for maintenance as well as Ventolin MDI as a rescue inhaler. * Stable asthma -not currently being evaluated for an acute asthma exacerbation and no Emergency Room visits for asthma within the last 30 days. * Adequate lung function with a FEV1 of at least 50% and, where available, a peak inspiratory flow (PIF) of under 60L/m for use of a DPI and MDI.
Where this trial is running
Montréal, Quebec
- McGill University Health Center — Montréal, Quebec, Canada (Recruiting)
Study contacts
- Study coordinator: Nicole EZER, MD
- Email: nicole.ezer@mcgill.ca
- Phone: (514)-934-1934
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.